Lv1
24 积分 2024-01-24 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
10小时前
待确认
FLAIR: A Phase II, Open label, Randomized Study of Osimertinib Plus Bevacizumab versus Osimertinib in Recurrent or Metastatic Treatment-naïve NSCLC Patients Harboring EGFR 21L858R Mutation
2天前
已完结
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
2天前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3天前
已完结
Chapter 44 - Role of the pharmacist in research
11天前
已关闭
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
2个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2个月前
已完结
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
2个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
2个月前
已完结
皖公网安备34019202002308
